Research fees will drive search for novel drug candidates for the treatment of Huntington’s disease until 2010.

Evotec signed a collaboration extension with CHDI Foundation, an organization focused on Huntington’s disease (HD). The foundation will pay up to $37 million in research fees related to this partnership, which will be in effect to the end of 2010.

Terms of the agreement cover Evotec’s biochemical and cellular assay development and high-content screening on interesting cell lines with the aim of identifying novel starting points for medicinal chemistry programs. Additionally, Evotec will continue to supply key support in the area of medicinal chemistry and biology optimization on multiple biological targets for the treatment of HD as the company generates lead molecules for subsequent progression into clinical trials.

Previous articleCurrent Pharma Model Shortchanges Patients
Next articleInvestigators Illuminate Mechanism of Immune Suppression in Staph Infection